Daphne Krzisch
Overview
Explore the profile of Daphne Krzisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Debureaux P, Poulain S, Harel S, Passet M, Temple M, Friedrich C, et al.
Blood
. 2024 Nov;
145(4):450-454.
PMID: 39571148
Inflammatory form of Waldenström macroglobulinemia (iWM) predicts outcomes after immuno-chemotherapy and Bruton tyrosine kinase inhibitors, but its origin is unknown. Here, we unravel increased clonal hematopoiesis in patients with iWM...
2.
Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M, et al.
Eur J Cancer
. 2024 Nov;
213():115073.
PMID: 39509848
Classic Hodgkin lymphoma (HL) is a distinct entity among hematological malignancies of B-cell origin. It is characterized by its unique histopathological features and generally favorable prognosis. Over the years, advancements...
3.
Juul S, Rossetti S, Aleman B, van Leeuwen F, van der Kaaij M, Giusti F, et al.
J Cancer Surviv
. 2024 Oct;
PMID: 39422824
Purpose: Studies looking into the concordance between late effects reported by physicians vs. those reported by Hodgkin lymphoma (HL) survivors are missing. Methods: A Life Situation Questionnaire focusing on late...
4.
Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, et al.
Blood Adv
. 2024 Aug;
8(20):5371-5381.
PMID: 39163620
Tafasitamab plus lenalidomide (TAFA-LEN) treatment relevance pre- or post-anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is debated. We analyzed patients with large B-cell lymphoma in the DESCAR-T registry treated with...
5.
Ghesquieres H, Krzisch D, Nicolas-Virelizier E, Kanoun S, Gac A, Guidez S, et al.
Blood
. 2023 Nov;
143(11):983-995.
PMID: 37979133
Older patients with classical Hodgkin lymphoma (cHL) require more effective and less toxic therapies than younger patients. In this multicenter, prospective, phase 2 study, we investigated a new firstline therapy...
6.
Bouclet F, Krzisch D, Leblond V, Tomowiak C, Laribi K, Ysebaert L, et al.
Bull Cancer
. 2022 Oct;
110(1):88-100.
PMID: 36229266
Waldenström's disease is a B-cell neoplasm characterized by the accumulation of lymphoplasmacytic cells (LPCs) in the bone marrow, and more rarely in the lymph nodes and the spleen, which produce...
7.
Forgeard N, Baron M, Caron J, Boccon-Gibod C, Krzisch D, Guedes N, et al.
Haematologica
. 2022 Jul;
107(11):2720-2724.
PMID: 35833301
No abstract available.
8.
Krzisch D, Guedes N, Boccon-Gibod C, Baron M, Bravetti C, Davi F, et al.
Am J Hematol
. 2021 Aug;
96(12):1569-1579.
PMID: 34462944
While Waldenström macroglobulinemia (WM) is characterized by an almost unifying mutation in MYD88, clinical presentation at diagnosis and response to therapy can be widely different among WM patients. Current prognostic...
9.
Gendron N, Dragon-Durey M, Chocron R, Darnige L, Jourdi G, Philippe A, et al.
Arthritis Rheumatol
. 2021 Apr;
73(11):1976-1985.
PMID: 33881229
Objective: The clinical relevance of antiphospholipid antibodies (aPLs) in COVID-19 is controversial. This study was undertaken to investigate the prevalence and prognostic value of conventional and nonconventional aPLs in patients...
10.
Penichoux J, Dubois S, Krzisch D, Menard A, Lanic H, Camus V, et al.
Leuk Lymphoma
. 2021 Apr;
62(9):2272-2275.
PMID: 33797310
No abstract available.